Trials / Completed
CompletedNCT00608699
A Study To See If GSK256073A Can Block Niacin-Induced Flushing In Healthy Volunteers
A Study to Evaluate the Ability of the HM74A Agonist GSK256073A to Block Niacin-induced Flushing in Healthy Adult Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- Male
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
To test the ability of GSK256073 to block niacin-induced flushing when GSK256073 and niacin are co-administered as single doses to HVTs.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GSK256073A tablets + IR niacin tablets | single dosing for 4 to 5 sessions |
Timeline
- Start date
- 2007-12-01
- Primary completion
- 2008-04-01
- Completion
- 2008-04-01
- First posted
- 2008-02-06
- Last updated
- 2012-04-30
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00608699. Inclusion in this directory is not an endorsement.